AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27982160 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Intervention (II)
Number of subjects: 72
Study 27982160 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 72
Study 26234491 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/PCL + Ag NFMs
Number of subjects: 0
Study 26234491 — intervention group
Group type: COMPARATOR
Intervention: PCL NFMs
Number of subjects: 0
Study 26234491 — intervention group
Group type: COMPARATOR
Intervention: HA/PCL NFMs
Number of subjects: 0
Study 23102711 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized interdisciplinary case conference including their GP
Number of subjects: 461
Study 23102711 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient/caregiver education about pain management
Number of subjects: 461
Study 23102711 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visiting for GPs about pain management
Number of subjects: 461
Study 23102711 — intervention group
Group type: COMPARATOR
Intervention: Control condition (current palliative care)
Number of subjects: 461
Study 20890699 — intervention group
Group type: EXPERIMENTAL
Intervention: Total synovectomy and total knee arthroplasty
Number of subjects: 50
Study 20890699 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty alone (Control)
Number of subjects: 50
Study 19851234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention tailoring activities
Number of subjects: 2
Study 19851234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention tailoring
Number of subjects: 2
Study 17091416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100
Study 17091416 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (Control)
Number of subjects: 100
Study 15207416 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg daily (in divided doses)
Number of subjects: 60
Study 15207416 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg at bedtime
Number of subjects: 60
Study 15207416 — intervention group
Group type: COMPARATOR
Intervention: Promazine 50 mg daily (in divided doses)
Number of subjects: 60
Study 11719836 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 59
Study 11719836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 59
Study 11719836 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 59
Study 9521941 — intervention group
Group type: EXPERIMENTAL
Intervention: PNCRM7
Number of subjects: 212
Study 9521941 — intervention group
Group type: COMPARATOR
Intervention: DTP/HbOC
Number of subjects: 212
Study 7976645 — intervention group
Group type: EXPERIMENTAL
Intervention: High oncotic pressure (HOP; 26‐30 mmHg) treatment
Number of subjects: 18
Study 7976645 — intervention group
Group type: COMPARATOR
Intervention: Normal oncotic pressure (NOP; 22‐26 mmHg) treatment
Number of subjects: 18
Study 2917587 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pipequaline
Number of subjects: 12
Study 2917587 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12
Study 2917587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate 5 mg single oral dose
Number of subjects: 10
Study 31544950 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week progressive resistance exercise intervention
Number of subjects: 75
Study 31544950 — intervention group
Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 75
Study 31544950 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (25 women)
Number of subjects: 75
Study 29070159 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch strategy
Number of subjects: 44
Study 29070159 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse strategy
Number of subjects: 44
Study 29070159 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 44
Study 29070159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion strategy influence
Number of subjects: 44
Study 25744325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 43
Study 25744325 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education (control group)
Number of subjects: 43
Study 23720992 — intervention group
Group type: EXPERIMENTAL
Intervention: OPD-CA interviews
Number of subjects: 39
Study 21453467 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Number of subjects: 35
Study 21453467 — intervention group
Group type: COMPARATOR
Intervention: Oral zinc sulfate-topical corticosteroid combination
Number of subjects: 35
Study 19700948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 25-80 mg/day
Number of subjects: 92
Study 19700948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 92
Study 19700948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 92
Study 16409328 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile rotary Nickel‐Titanium (Ni‐Ti) instruments
Number of subjects: 48
Study 16409328 — intervention group
Group type: COMPARATOR
Intervention: H‐files combined with Gates‐Glidden (GG) drills
Number of subjects: 48
Study 16409328 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26 sealer
Number of subjects: 48
Study 16409328 — intervention group
Group type: EXPERIMENTAL
Intervention: Endion sealer
Number of subjects: 48
Study 16409328 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 811 sealer
Number of subjects: 48
Study 16409328 — intervention group
Group type: EXPERIMENTAL
Intervention: Roekoseal sealer
Number of subjects: 48
Study 15307699 — intervention group
Group type: EXPERIMENTAL
Intervention: Luohuo capsule (LHC)
Number of subjects: 90
Study 15307699 — intervention group
Group type: COMPARATOR
Intervention: Beijing Hypotension No. 0
Number of subjects: 90
Study 11175492 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofibrate (500 mg twice daily)
Number of subjects: 25
Study 11175492 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release niacin (500 mg twice daily)
Number of subjects: 25
Study 9425675 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic processing of surfaces with different property classes (material, abrupt-surface discontinuity, relative orientation, continuous 3-D surface contour)
Number of subjects: 15
Study 8356936 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 66
Study 8356936 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 66
Study 3667024 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 3667024 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 3667024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31845131 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent questionnaire
Number of subjects: 0
Study 31845131 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concerns
Number of subjects: 0
Study 31845131 — intervention group
Group type: EXPERIMENTAL
Intervention: Examiner-led assessment
Number of subjects: 0
Study 31845131 — intervention group
Group type: COMPARATOR
Intervention: Total and individual item scores from the questionnaire and interactive assessment
Number of subjects: 0
Study 29131677 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 35
Study 29131677 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 35
Study 29131677 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 35
Study 27269043 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg
Number of subjects: 834
Study 27269043 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 834
Study 27269043 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 25 mg
Number of subjects: 834
Study 27269043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 834
Study 24888659 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal xylitol consumption (chewing xylitol gum, 1.8 gram, 66% xylitol by weight, 3 times/day for 3 months)
Number of subjects: 60
Study 24888659 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60
Study 24295141 — intervention group
Group type: EXPERIMENTAL
Intervention: practice‐based intervention
Number of subjects: 90
Study 24295141 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 90
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 microg once daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 10 microg once daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 microg once daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 30 microg once daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 microg twice daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 10 microg twice daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 microg twice daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 30 microg twice daily
Number of subjects: 542
Study 20722676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 18401602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate gel (CHX)
Number of subjects: 138
Study 18401602 — intervention group
Group type: COMPARATOR
Intervention: calcium hydroxide/camphorated paramonochlorophenol/glycerin paste (CH/CPMC)
Number of subjects: 138
Study 18401602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 138
Study 16372263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C supplementation (250 mg three times per week)
Number of subjects: 0
Study 16372263 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal renal function
Number of subjects: 0
Study 14662011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 11
Study 14662011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 11
Study 11113618 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antioxidant supplements
Number of subjects: 0
Study 11113618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study 9026680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-time ultralente insulin (0.15-0.2 U/kg)
Number of subjects: 0
Study 9026680 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (0.15-0.2 U/kg)
Number of subjects: 0
Study 7930304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 1000
Study 7930304 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 1000
Study 7930304 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroids
Number of subjects: 1000
Study 3370851 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐menthol
Number of subjects: 40
Study 3370851 — intervention group
Group type: COMPARATOR
Intervention: D‐isomenthol
Number of subjects: 40
Study 3370851 — intervention group
Group type: COMPARATOR
Intervention: D‐neomenthol
Number of subjects: 40
Study 31625399 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 675
Study 31625399 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 675
Study 31625399 — intervention group
Group type: COMPARATOR
Intervention: Pap-smear
Number of subjects: 675
Study 31625399 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 675
Study 31625399 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative women
Number of subjects: 675
Study 30152415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care group (PCG)
Number of subjects: 153
Study 30152415 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 153
Study 28259590 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg/day of Plasmalogen (Pls) purified from scallop
Number of subjects: 328
Study 28259590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 26444127 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 703
Study 26444127 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel IUD
Number of subjects: 703
Study 23277307 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with drug eluting stents (DES-PCI)
Number of subjects: 1900
Study 23277307 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study 21623673 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analog (SA) treatment for 4 weeks
Number of subjects: 12
Study 21623673 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects), N=12
Number of subjects: 12
Study 19257967 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus mature dendritic cells (mDC) in MG patients
Number of subjects: 39
Study 19257967 — intervention group
Group type: COMPARATOR
Intervention: Thymus mature dendritic cells (mDC) in control patients
Number of subjects: 39
Study 16492920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1549
Study 16492920 — intervention group
Group type: EXPERIMENTAL
Intervention: XPC polymorphisms (R492H, A499V, K939Q)
Number of subjects: 1549
Study 16492920 — intervention group
Group type: COMPARATOR
Intervention: None of the studied SNPs
Number of subjects: 1549
Study 12951363 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet (28% fat)
Number of subjects: 18
Study 12951363 — intervention group
Group type: COMPARATOR
Intervention: Western diet (38% fat)
Number of subjects: 18
Study 11110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (3.4 g per day)
Number of subjects: 60
Study 11110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (6.8 g per day)
Number of subjects: 60
Study 11110851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9 g olive oil)
Number of subjects: 60
Study 7761220 — intervention group
Group type: EXPERIMENTAL
Intervention: HIDS phototherapy (26 to 30 microW/cm2 per nanometer)
Number of subjects: 50
Study 7761220 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (CPT) (7 to 10 microW/cm2 per nanometer)
Number of subjects: 50
Study 2186660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam (0.5 mg/kg)
Number of subjects: 149
Study 2186660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimeprazine (4 mg/kg)
Number of subjects: 149
Study 2186660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentobarbitone (3 mg/kg)
Number of subjects: 149
Study 2186660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 450929 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (8 microgram/kg)
Number of subjects: 70
Study 450929 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (0.2 mg/kg or 0.3 mg/kg)
Number of subjects: 70
Study 450929 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (32 microgram/kg)
Number of subjects: 70
Study 450929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31486832 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 every 21 days) plus Sorafenib (400 mg orally twice daily)
Number of subjects: 356
Study 31486832 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 356
Study 28457021 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist (CP) intervention
Number of subjects: 593
Study 28457021 — intervention group
Group type: COMPARATOR
Intervention: Usual care (prospective control)
Number of subjects: 593
Study 28457021 — intervention group
Group type: COMPARATOR
Intervention: Usual care (retrospective control)
Number of subjects: 593
Study 26366966 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (1:3)
Number of subjects: 46
Study 26366966 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (1:1.7)
Number of subjects: 46
Study 26366966 — intervention group
Group type: COMPARATOR
Intervention: Dysport
Number of subjects: 46
Study 23886720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education from the Dentist (Group A)
Number of subjects: 100
Study 23886720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education from the class teacher trained by the Dentist (Group B)
Number of subjects: 100
Study 23886720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education from dental residents dressed as cartoon characters (Group C)
Number of subjects: 100
Study 23886720 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 100
Study 21742105 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2974
Study 21742105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS)
Number of subjects: 2974
Study 21742105 — intervention group
Group type: COMPARATOR
Intervention: Overall lesions treated with PES and BMS
Number of subjects: 2974
Study 19619102 — intervention group
Group type: EXPERIMENTAL
Intervention: PHC-based interventions for unemployed people, details on dosage and duration not available.
Number of subjects: 0
Study 18035194 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
Number of subjects: 1072
Study 18035194 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
Number of subjects: 1072
Study 14709948 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200-1200 mg/d)
Number of subjects: 49
Study 14709948 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1-6 mg/d)
Number of subjects: 49
Study 11703994 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance walked in 6 minutes at baseline
Number of subjects: 440
Study 11703994 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance walked in 6 minutes at 1 month
Number of subjects: 440
Study 11703994 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in distance walked from baseline to 1 month
Number of subjects: 440
Study 11703994 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline distance walked
Number of subjects: 440
Study 9645549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 28
Study 7859241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosufloxacin 150 mg orally three times daily
Number of subjects: 63
Study 7859241 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg orally twice daily
Number of subjects: 63
Study 2660783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 60
Study 2660783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 5539179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 38
Study 5539179 — intervention group
Group type: COMPARATOR
Intervention: Debrisoquine
Number of subjects: 38
Study 5539179 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 38
Study 31981518 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDOANGEL-assisted colonoscopy
Number of subjects: 704
Study 31981518 — intervention group
Group type: COMPARATOR
Intervention: Unassisted colonoscopy (control)
Number of subjects: 704
Study 31468607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training (35 min, three times a week for 6 weeks, increasing to 45 min after 3 weeks)
Number of subjects: 23
Study 31468607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training
Number of subjects: 23
Study 31468607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study 29119733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3.5 μg/kg via slow intravenous fluid line
Number of subjects: 1200
Study 29119733 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 3.5 μg/kg via direct injection (control group)
Number of subjects: 1200
Study 25311306 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus PCV chemotherapy
Number of subjects: 288
Study 25311306 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite loss (AP)
Number of subjects: 288
Study 23138961 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management for stimulant abstinence plus treatment as usual
Number of subjects: 176
Study 23138961 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual with reinforcement for study participation only
Number of subjects: 176
Study 21554991 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 260
Study 21554991 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 260
Study 21554991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 260
Study 19198737 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed physical activity
Number of subjects: 383
Study 19198737 — intervention group
Group type: COMPARATOR
Intervention: Conventional school physical education (Control)
Number of subjects: 383
Study 16968575 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day plus metformin 1000 mg/day (RSG + MET)
Number of subjects: 122
Study 16968575 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1500 mg/day (up-titrated MET)
Number of subjects: 122
Study 14556556 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptamen nutriment
Number of subjects: 0
Study 14556556 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0